Global Central Nervous System Therapeutics Market is valued at approximately USD 143.95 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.5% over the forecast period 2024-2032. Central Nervous System (CNS) Therapeutics refers to a range of medications, treatments, and therapies designed to diagnose, manage, and treat disorders and diseases affecting the central nervous system. The CNS, which includes the brain and spinal cord, controls most of the body's functions, including thought processes, motor skills, and sensory perception. CNS therapeutics encompass a variety of approaches, such as pharmaceuticals, biologics, gene therapies, and medical devices, targeting conditions like Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, depression, schizophrenia, and other neurological or psychiatric disorders. The aim is to alleviate symptoms, slow disease progression, or restore normal CNS function.
Advancements in the diagnostics and therapeutics of CNS diseases have revolutionized treatment approaches globally. Rising awareness regarding CNS disorders, coupled with the growing prevalence of conditions such as Alzheimer's, multiple sclerosis, epilepsy, and Parkinson's disease, continues to drive demand for effective therapeutic options. According to the World Health Organization (WHO), more than one billion people are affected by CNS disorders worldwide, further underscoring the substantial unmet medical need in this market. Moreover, the increasing awareness of mental health and neurodegenerative diseases, combined with government initiatives, is further supporting the growth of the CNS therapeutics market. However, the regulatory hurdles and high cost of different therapies are challenging the market growth throughout the forecast period of 2024-2032.
Regionally, North America remains the largest market for CNS therapeutics, driven by the presence of key players, advanced healthcare infrastructure, and awareness campaigns that focus on CNS disease diagnosis and treatment. Asia Pacific, however, is poised to experience the highest growth rate, supported by improvements in healthcare infrastructure, increased awareness, and a large patient base with unmet medical needs in countries such as China and India.
Major Market Players Included in This Report:
Biogen
Otsuka Pharmaceutical Co., Ltd.
Eli Lilly and Company
Johnson & Johnson Services, Inc.
Pfizer, Inc.
Novartis International AG
Roche Holding AG
Teva Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Bristol-Myers Squibb Company
AbbVie Inc.
Sanofi S.A.
Amgen Inc.
AstraZeneca PLC
GlaxoSmithKline plc (GSK)
The detailed segments and sub-segment of the market are explained below:
By Disease Outlook:
Neurovascular Diseases
CNS Trauma
Mental Health
Neurodegenerative Diseases
Infectious Diseases
CNS Cancer
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approaches.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.